Sorafenib for recent-onset T1D
What it is
A kinase-inhibitor repurposing study asks whether sorafenib can preserve insulin production. The small Phase 2 registry still says not yet recruiting; no T1D results are posted.
Editorial review: . What was checked and what remains uncertain.
Latest dated source in the citation list: 2026-02-12. This is the source’s date, not a new review of every claim.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Beta-cell preservation: No T1D efficacy result is posted; C-peptide preservation is the study question.[1]
- Important harms and treatment burden
- Safety: Known label risks include cardiovascular events, bleeding, hypertension, severe skin effects and liver injury; T1D benefit-risk is unknown.[2]
- Approval and country access
- A kinase-inhibitor repurposing study asks whether sorafenib can preserve insulin production. The small Phase 2 registry still says not yet recruiting; no T1D results are posted.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: There is no demonstrated durable T1D benefit.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 8 × 30 + 8 × 20 + 15 × 20 + 20 × 10 + 15 × 20 = 1200; divide by total weight 100. Unrounded weighted result: 12.
No T1D efficacy result is posted; C-peptide preservation is the study question.[1]
Known label risks include cardiovascular events, bleeding, hypertension, severe skin effects and liver injury; T1D benefit-risk is unknown.[2]
The proposed trial selects adults 18–60 within one year of diagnosis, with residual C-peptide and extensive safety exclusions.[1]
Registered Phase 2 with ten participants planned, but still not yet recruiting in the latest update.[1]
The full picture
A registered question, with no clinical answer yet
NCT06227221 plans to compare sorafenib with placebo while continuing insulin. Its estimated start date has passed, but the latest registry status remains not yet recruiting. The planned sample is ten adults; this is not a report of ten treated participants. Estimated primary completion is October 2028.1
Sorafenib is grouped with immune-pathway drug repurposing here; that editorial category does not prove a selective immune mechanism or T1D efficacy. The verified registry supplies the trial question, eligibility and status, not a demonstrated treatment effect.
Why safety weighs heavily
The US Nexavar label concerns liver, kidney and thyroid cancers. It warns about cardiovascular events, haemorrhage, hypertension, dermatologic toxicity, gastrointestinal perforation, QT prolongation, liver injury and fetal harm, among other risks. Its use in cancer cannot establish an acceptable benefit-risk balance for otherwise healthy people with recent-onset T1D. This is not an insulin replacement or a licensed T1D indication.2
Sources
- [1]NCT06227221 — study record · registry · 2026-02-12 — Registry update date; retrieved 16 September 2026. Registry registration is not proof of clinical benefit.
- [2]Nexavar (sorafenib) US prescribing information, revised August 2023 · regulatory — Cancer indications and drug warnings; not a T1D approval or T1D outcome study.